- Home
- GRRR vs ARVN Comparison
GRRR vs ARVN Comparison
Compare GRRR & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRRR
- ARVN
- Stock Information
- Founded
- GRRR 2001
- ARVN 2015
- Country
- GRRR United Kingdom
- ARVN United States
- Employees
- GRRR N/A
- ARVN N/A
- Industry
- GRRR Computer Software: Prepackaged Software
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- GRRR Technology
- ARVN Health Care
- Exchange
- GRRR Nasdaq
- ARVN Nasdaq
- Market Cap
- GRRR 417.6M
- ARVN 456.2M
- IPO Year
- GRRR N/A
- ARVN 2018
- Fundamental
- Price
- GRRR $15.98
- ARVN $7.42
- Analyst Decision
- GRRR Buy
- ARVN Buy
- Analyst Count
- GRRR 1
- ARVN 21
- Target Price
- GRRR $18.00
- ARVN $20.53
- AVG Volume (30 Days)
- GRRR 2.1M
- ARVN 1.9M
- Earning Date
- GRRR 09-29-2025
- ARVN 08-06-2025
- Dividend Yield
- GRRR N/A
- ARVN N/A
- EPS Growth
- GRRR N/A
- ARVN N/A
- EPS
- GRRR N/A
- ARVN N/A
- Revenue
- GRRR $84,196,961.00
- ARVN $426,900,000.00
- Revenue This Year
- GRRR $38.13
- ARVN $7.57
- Revenue Next Year
- GRRR $28.55
- ARVN N/A
- P/E Ratio
- GRRR N/A
- ARVN N/A
- Revenue Growth
- GRRR 19.91
- ARVN 498.74
- 52 Week Low
- GRRR $2.09
- ARVN $5.90
- 52 Week High
- GRRR $44.15
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- GRRR 36.56
- ARVN 45.30
- Support Level
- GRRR $17.48
- ARVN $7.41
- Resistance Level
- GRRR $17.15
- ARVN $8.15
- Average True Range (ATR)
- GRRR 0.95
- ARVN 0.39
- MACD
- GRRR -0.37
- ARVN -0.04
- Stochastic Oscillator
- GRRR 8.29
- ARVN 21.08
About GRRR Gorilla Technology Group Inc.
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.